Drug Pricing In The Next Senate: Incoming Finance Chair Grassley Outlines Priorities
Executive Summary
A key figure in determining what Rx bills advance in Congress, Grassley recently expressed interest in working with House Democrats in a floor speech on his drug pricing priorities.
You may also be interested in...
HHS Rebate Rule: At Least We Know Who Is In Charge
HHS proposal to eliminate the “safe harbor” that allows for prescription drug rebates took a long time to clear White House review. Its release sends a clear message that US HHS Secretary Azar wants to lead the drug pricing debate in 2019.
A Big Day For Drug Pricing: Senate Hearing Will Overlap With House Committee’s
Senate Finance Committee's Jan. 29 witnesses will include economists, a patient advocate and “others,” to be announced in the coming days, panel says.
PhRMA Adds Genentech, Gilead To Its Ranks Ahead Of House Democrats’ Drug Pricing Scrutiny
Roche, through Genentech, returns to the PhRMA fold after leaving the trade group in 2009; Gilead is a first-time member; both are retaining their BIO memberships as well.